Hypoaldosteronism pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 103: Line 103:


==Associated Conditions==
==Associated Conditions==
*Sickle cell disease
*[[Sickle-cell disease|Sickle cell disease]]
*Analgesic nephropathy
*[[Analgesic nephropathy]]
*Lead nephropathy
*Lead nephropathy
*Chronic pyelonephritis
*[[Chronic pyelonephritis]]
*Obstructive nephropathy
*[[Obstructive nephropathy]]
*Diabetes and renal insufficiency
*[[Diabetes]] and [[renal insufficiency]]
*Nonsteroidal anti-inflammatory drugs
*[[Nonsteroidal anti-inflammatory drugs]]
*Calcineurin inhibitors
*[[Calcineurin inhibitor|Calcineurin inhibitors]]
*Vitiligo
*[[Vitiligo]]
*Premature ovarian failure
*[[Premature ovarian failure]]
*Pernicious anemia
*[[Pernicious anemia]]
*Myasthenia gravis
*[[Myasthenia gravis]]
*Chronic candidiasis
*Chronic [[candidiasis]]
*Sjögren syndrome
*[[Sjögren's syndrome|Sjögren syndrome]]
*Chronic active hepatitis
*[[Chronic active hepatitis]]
*Hypothyroidism
*[[Hypothyroidism]]
*Graves hyperthyroidism
*[[Graves' disease|Graves]] hyperthyroidism
*Adrenoleukodystrophy
*[[Adrenoleukodystrophy]]


==Gross Pathology==
==Gross Pathology==
*On gross pathology, adrenal glands in hypoaldosteronism can either be:
*On [[gross pathology]], [[adrenal glands]] in hypoaldosteronism can either be:
**Irregularly shrunken, or
**Irregularly shrunken, or
**Hyperplastic
**[[Hyperplastic]]
[[image:Adrenal glands.jpg|400px|center|Image courtesy: PathologyOutlines.com]]
[[image:Adrenal glands.jpg|400px|center|Image courtesy: PathologyOutlines.com]]


==Microscopic Pathology==
==Microscopic Pathology==
*On microscopic histopathological analysis, adrenal gland can be divided into adrenal cortex and adrenal medulla.
*On [[microscopic]] [[histopathological]] analysis, [[adrenal gland]] can be divided into [[adrenal cortex]] and [[adrenal medulla]].
*Adrenal cortex can be further categorized into:
*[[Adrenal cortex]] can be further categorized into:
**Zona glomerulosa (produces aldosterone)
**[[Zona glomerulosa]] (produces [[aldosterone]])
**Zona fasciculata (produces cortisol)
**[[Zona fasciculata]] (produces [[cortisol]])
**Zona reticularis (produces androgens)
**[[Zona reticularis]] (produces [[androgens]])
[[image:Adrenal glands normal histology.jpg|400px|center|Image courtesy: PathologyOutlines.com]]
[[image:Adrenal glands normal histology.jpg|400px|center|Image courtesy: PathologyOutlines.com]]



Revision as of 20:37, 30 August 2017

Hypoaldosteronism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypoaldosteronism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypoaldosteronism pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hypoaldosteronism pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypoaldosteronism pathophysiology

CDC on Hypoaldosteronism pathophysiology

Hypoaldosteronism pathophysiology in the news

Blogs on Hypoaldosteronism pathophysiology

Directions to Hospitals Treating Hypoaldosteronism

Risk calculators and risk factors for Hypoaldosteronism pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

Hypoaldosteronism is defined as decreased levels of the hormone aldosterone or a resistance of the target tissue to the actions of aldosterone. Hypoaldosteronism from decreased production is seen in conditions such as congenital isolated hypoaldosteronism, primary adrenal insufficiency, diabetic nephropathy, critical illness, and drugs such as ACE inhibitors, NSAIDs and calcineurin inhibitors. Resistance of the target tissue to the actions of aldosterone is seen with mineralocorticoid receptor defects (seen in pseudohypoaldosteronism) and with drugs such as potassium-sparing diuretics and trimethoprim. Hypoaldosteronism results in reduced reabsorption of sodium in the principal cells of cortical collecting tubules (CCT). This leads to decreased excretion of potassium (hyperkalemia) and mild non-anion gap metabolic acidosis. On gross pathology, adrenal glands may be irregularly shrunken or hyperplastic.

Pathophysiology

Physiology


Source:By A. Rad (me) (Own work) [GFDL (http://www.gnu.org/copyleft/fdl.html) or CC-BY-SA-3.0 (http://creativecommons.org/licenses/by-sa/3.0/)], via Wikimedia Commons


Pathogenesis

Hyporeninemic Hypoaldosteronism

Hyperreninemic Hypoaldosteronism

Isolated Hypoaldosteronism

Postadrenalectomy Hypoaldosteronism

Postadrenalectomy hypoaldosteronism is seen in patients with Conn syndrome who undergo surgery for tumor removal:[5][6][7][8][9][10][11]

Mineralocorticoid Resistance

Mineralocorticoid resistance is characterized by a decrease in response to the hormone aldosterone. In mineralocorticoid resistance the level of aldosterone may be normal or supranormal. It is due to this reason mineralocorticoid resistance is also known as pseudohypoaldosteronism. Mineralocorticoid resistance can be further categorized into:[12][13][14]

  • Pseudohypoaldosteronism type I:
    • The decrease in response to aldosterone is due to heterozygous or homozygous inactivating mutations in the mineralocorticoid receptor. These patients are also resistant to mineralocorticoid therapy.
  • Pseudohypoaldosteronism Type II:
    • This is an extremely rare disorder. It is speculated that these patients have mutations in the genes encoding proteins of the serine threonine kinase family (WKNK1 or WNK4 kinases). Pseudohypoaldosteronism Type II is characterized by low or low-normal plasma renin activity and aldosterone concentrations, leading to hyperkalemia and metabolic acidosis with normal renal function. Pseudohypoaldosteronism type II is also known as Gordon’s syndrome.
  • Pseudohypoaldosteronism type III:
    • This condition presents with transient mineralocorticoid resistance. Pseudohypoaldosteronism type III is seen in patients with underlying renal conditions with decreased GFR. The exact cause is unknown but is thought to be related to increased levels of TGF-β.

Genetics


 
 
 
11 Deoxycorticosterone
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corticosterone
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18 Hydroxycorticosterone
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aldosterone
 
 
 


Associated Conditions

Gross Pathology

Image courtesy: PathologyOutlines.com
Image courtesy: PathologyOutlines.com

Microscopic Pathology

Image courtesy: PathologyOutlines.com
Image courtesy: PathologyOutlines.com

References

  1. White PC (1994). "Disorders of aldosterone biosynthesis and action". N. Engl. J. Med. 331 (4): 250–8. doi:10.1056/NEJM199407283310408. PMID 8015573.
  2. Kater CE, Biglieri EG, Brust N, Chang B, Hirai J (1982). "Regulation of the mineralocorticoid hormones in adrenocortical disorders with adrenocorticotropin excess". Clin Exp Hypertens A. 4 (9–10): 1749–58. PMID 6291814.
  3. Aguilera G, Fujita K, Catt KJ (1981). "Mechanisms of inhibition of aldosterone secretion by adrenocorticotropin". Endocrinology. 108 (2): 522–8. doi:10.1210/endo-108-2-522. PMID 6256154.
  4. Singer DR, Shirley DG, Markandu ND, Miller MA, Buckley MG, Sugden AL, Sagnella GA, MacGregor GA (1991). "How important are suppression of aldosterone and stimulation of atrial natriuretic peptide secretion in the natriuretic response to an acute sodium load in man?". Clin. Sci. 80 (4): 293–9. PMID 1851063.
  5. Kawasaki T, Uezono K, Ueno M, Noda Y, Kumamoto K, Kawano Y, Ogata M, Fukiyama K, Omae T, Bartter FC (1980). "Influence of unilateral adrenalectomy on renin-angiotensin-aldosterone system in primary aldosteronism". Jpn Heart J. 21 (5): 681–92. PMID 7001091.
  6. Kempers MJ, Lenders JW, van Outheusden L, van der Wilt GJ, Schultze Kool LJ, Hermus AR, Deinum J (2009). "Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism". Ann. Intern. Med. 151 (5): 329–37. PMID 19721021.
  7. Huang WT, Chau T, Wu ST, Lin SH (2010). "Prolonged hyperkalemia following unilateral adrenalectomy for primary hyperaldosteronism". Clin. Nephrol. 73 (5): 392–7. PMID 20420801.
  8. Gadallah MF, Kayyas Y, Boules F (1998). "Reversible suppression of the renin-aldosterone axis after unilateral adrenalectomy for adrenal adenoma". Am. J. Kidney Dis. 32 (1): 160–3. PMID 9669438.
  9. Biglieri EG, Slaton PE, Silen WS, Galante M, Forsham PH (1966). "Postoperative studies of adrenal function in primary aldosteronism". J. Clin. Endocrinol. Metab. 26 (5): 553–8. doi:10.1210/jcem-26-5-553. PMID 4287160.
  10. Groth H, Vetter W, Stimpel M, Greminger P, Tenschert W, Klaiber E, Vetter H (1985). "Adrenalectomy in primary aldosteronism: a long-term follow-up study". Cardiology. 72 Suppl 1: 107–16. PMID 3902226.
  11. Yorke E, Stafford S, Holmes D, Sheth S, Melck A (2015). "Aldosterone deficiency after unilateral adrenalectomy for Conn's syndrome: a case report and literature review". Int J Surg Case Rep. 7C: 141–4. doi:10.1016/j.ijscr.2015.01.013. PMC 4336421. PMID 25604311.
  12. CHEEK DB, PERRY JW (1958). "A salt wasting syndrome in infancy". Arch. Dis. Child. 33 (169): 252–6. PMC 2012226. PMID 13545877.
  13. Wilson FH, Disse-Nicodème S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, Gunel M, Milford DV, Lipkin GW, Achard JM, Feely MP, Dussol B, Berland Y, Unwin RJ, Mayan H, Simon DB, Farfel Z, Jeunemaitre X, Lifton RP (2001). "Human hypertension caused by mutations in WNK kinases". Science. 293 (5532): 1107–12. doi:10.1126/science.1062844. PMID 11498583.
  14. Wakabayashi M, Mori T, Isobe K, Sohara E, Susa K, Araki Y, Chiga M, Kikuchi E, Nomura N, Mori Y, Matsuo H, Murata T, Nomura S, Asano T, Kawaguchi H, Nonoyama S, Rai T, Sasaki S, Uchida S (2013). "Impaired KLHL3-mediated ubiquitination of WNK4 causes human hypertension". Cell Rep. 3 (3): 858–68. doi:10.1016/j.celrep.2013.02.024. PMID 23453970.

Template:WH Template:WS